Abstract Hemorrhagic transformation (HT) is a devastating complication for patients with acute ischemic stroke who are treated with tissue plasminogen activator (tPA). It is associated with high morbidity and mortality, but no effective treatments are currently available to reduce HT risk. Therefore, methods to prevent HT are urgently needed. In this study, we used TWS119, an inhibitor of glycogen synthase kinase 3β (GSK-3β), to evaluate the role of the Wnt/β-catenin signaling pathway in recombinant tPA (rtPA)-induced HT. SpragueDawley rats were subjected to a middle cerebral artery occlusion (MCAO) model of ischemic stroke and then were administered rtPA, rtPA combined with TWS119, or vehicle at 4 h. The animals were sacrificed 24 h after infarct induction. Rats treated with rtPA showed evident HT, had more severe neurologic deficit, brain edema, and blood-brain barrier breakdown, and had larger infarction volume than did the vehicle group. Rats treated with TWS119 had significantly improved outcomes compared with those of rats treated with rtPA alone. In addition, Western blot analysis showed that TWS119 increased the protein expression of β-catenin, claudin-3, and ZO-1 while suppressing the expression of GSK-3β. These results suggest that TWS119 reduces rtPA-induced HT and attenuates blood-brain barrier disruption, possibly through activation of the Wnt/β-catenin signaling pathway. This study provides a potential therapeutic strategy to prevent tPAinduced HT after acute ischemic stroke.
Introduction
Hemorrhagic transformation (HT) is a major complication of acute ischemic stroke that occurs in 10 to 40 % of patients [1] . The risk of HT is even higher in patients treated with tissue plasminogen activator (tPA), the only therapy for ischemic stroke approved by the United States Food and Drug Administration [2] . Although many preclinical studies have attempted to find ways of reducing HT risk, no effective treatment has yet been developed. Therefore, research into the mechanisms of HT and into potential therapies that could reduce HT risk and improve prognosis of patients with acute ischemic stroke is greatly needed.
Previous studies have focused primarily on breakdown of the blood-brain barrier (BBB) after acute ischemic stroke [3] [4] [5] . Evidence has shown that tPA aggravates disruption of the BBB and increases the risk of HT [6] [7] [8] . Therefore, protection of the BBB is crucial to reducing the risk of tPAinduced HT.
It has been shown that a dysfunctional Wnt/β-catenin signaling pathway contributes to breakdown of the BBB and that activation of signaling limits the effects of BBB breakdown in degenerative and inflammatory diseases of the brain [9] [10] [11] . However, the role of Wnt/β-catenin signaling in the BBB Wei Wang and Mingchang Li contributed equally to this work.
* Qianxue Chen chenqx666@sohu.com * Jian Wang jwang79@jhmi.edu breakdown during post-stroke HT is unknown. Glycogen synthase kinase 3β (GSK-3β), a component of the adenomatous polyposis coli/axin/GSK-3β complex, is involved in the ubiquitination and proteasomal degradation of β-catenin, which is the key molecule of the Wnt/β-catenin pathway [12] [13] [14] . In this study, to investigate the role of the Wnt/β-catenin pathway in tPA-induced HT, we used 4,6-disubstituted pyrrolo-pyrimidine (TWS119), a specific inhibitor of GSK-3β, to increase the protein level of β-catenin and activate the Wnt signaling pathway. We used a rat middle cerebral artery occlusion (MCAO) model to mimic the clinical scenario of acute ischemic stroke and administered recombinant tPA (rtPA) or rtPA plus TWS119. Our results showed that activation of the Wnt/β-catenin signaling pathway can improve early neurologic function, relieve cerebral edema, decrease permeability of the BBB, and reduce the risk of HT at 24 h after MCAO. We propose that the administration of TWS119 may become a potential clinical treatment to reduce the risk of HT and improve the prognosis of patients with acute ischemic stroke.
Materials and Methods

Animals
All protocols used in this study were approved by the Institutional Animal Care and Use Committee at Wuhan University. Adult male Sprague-Dawley rats weighing 250-280 g were purchased from the Wuhan University Center for Animal Experiments and housed under standard conditions with a 12:12 h light/dark cycle. Food and water were provided to all animals ad libitum. The operators were blinded to the treatment status of the animals in all experiments.
Cerebral Ischemia
Permanent focal cerebral ischemia was produced by endovascular occlusion of the left middle cerebral artery (MCAO) as described previously [15] . Briefly, animals were anesthetized by intraperitoneal injection of pentobarbital sodium (Dainippon Sumitomo Pharma, Osaka, Japan). Body temperature was maintained at 36.5-37.5°C throughout surgery. After a midline neck incision, the left common carotid artery was isolated under a microscope and ligated with a 4-0 silk suture (Ethicon, Issy-Les-Moulineaux, France). The external and internal carotid arteries were temporarily ligated with a 4-0 silk suture. An arteriotomy was performed proximal to the bifurcation of the common carotid artery. A silicone-coated nylon monofilament (40 mm long, 0.26 mm diameter, Beijing Sunbio Biotech, China) was introduced through the arteriotomy and advanced into the internal carotid artery up to a distance of 18-20 mm to occlude the origin of the middle cerebral artery. Four hours after this procedure, the rats were reanesthetized and the middle cerebral artery blood flow was restored by withdrawing the nylon monofilament. After surgery, the rats were returned to their home cages and maintained at 30°C with free access to food and water.
Experimental Groups and Drugs
All rats (136) were randomly divided into four groups as follows: Sham group-rats underwent the same surgical procedure, but the filament was not inserted and they received 1 mL of dimethyl sulfoxide (1 % DMSO in saline); Vehicle grouprats underwent MCAO and received 1 mL of DMSO; rtPA group-rats underwent MCAO and received rtPA (10 mg/kg, Actilyse®, Boehringer-Ingelheim, Biberach an der Reiss, Germany) at 4 h after MCAO; and rtPA+TWS119 grouprats underwent MCAO and received intraperitoneal TWS119 (30 mg/kg, dissolved in 1 mL 1 % DMSO, Selleck, Houston, TX, USA) [16, 17] immediately after rtPA injection at 4 h after MCAO.
Neurologic Deficit Score
An investigator blinded to experimental group examined the animals for neurologic function at 24 h after MCAO using a modified scoring system that was developed by Longa [18] . Scoring was as follows: 0, no deficits; 1, difficulty in fully extending the contralateral forelimb; 2, unable to extend the contralateral forelimb; 3, mild circling to the contralateral side; 4, severe circling; and 5, falling to the contralateral side. The higher the neurologic deficit score, the more severe impairment of motor function.
Brain Water Content
Brain water content was measured with the standard wet-dry method [19, 20] . Rats were anesthetized and sacrificed by decapitation at 24 h after MCAO. The brains were quickly removed and placed on a dry surface. After a 4-mm-thick section of frontal pole was dissected, the brain was cut with a brain slicer (Beijing Sunny Instrument Co., Ltd., Beijing, China) and divided into the ipsilateral and contralateral hemispheres. The two hemisphere slices were wrapped in preweighed aluminum foil and immediately weighed on an electronic balance to obtain the wet weight. After they were dried for 24 h in an oven at 100°C, they were reweighed to obtain the dry weight. Brain water content was calculated as a percentage using the following formula: (wet weight−dry weight)/wet weight×100 % [20, 21] .
Brain Infarct Volume
Infarct volume after MCAO was determined by 2,3,5-triphenyltetrazolium chloride (TTC, Sigma-Aldrich, St. Louis, MO)
staining at 24 h after MCAO. Animals were euthanized and sacrificed, and the brains were quickly removed. Brain tissue was sliced into seven coronal sections (2 mm thick), stained with a 2 % solution of TTC at 37°C for 20 min, and then fixed in 4 % paraformaldehyde. Normal tissue was stained red, whereas the infarct area remained a pale gray color. A different solution of TTC (1 %) was used to reveal the hemorrhage/ bleeding in the infarct area on the frozen brain sections [22, 23] . TTC-stained sections were photographed, and Image J image-processing software (NIH, Bethesda, MD) was used to calculate the infarct volume. The ratio of infarct volume= infarct area of the ipsilateral hemisphere/total area of the ipsilateral hemisphere×100 % [24, 25] .
Evaluation of BBB Permeability
Evans blue (EB) dye (2 %, 3 mL/kg, Sigma-Aldrich) was administered intravenously 3 h before the brain was harvested.
After the brain was perfused with saline, each hemisphere was weighed and homogenized in 4 mL of 50 % trichloroacetic acid solution. Then the homogenate was centrifuged at 10, 000g for 30 min, and the supernatant was collected and diluted with ethanol (1:3). EB content was determined on a spectrophotometer (Epoch™&Take3™, Biotek, USA) at 620 nm and calculated from a standard curve of EB. EB extravasation was expressed as EB extravasation index (EBI): the ratio of absorbance intensity in the ischemic hemisphere to that in the nonischemic hemisphere [26] .
Spectrophotometric Assay of Hemoglobin Content
Rats were administered an overdose of pentobarbital sodium and transcardially perfused with cold saline at 20 h after reperfusion. Brains were immediately removed and cut into the ipsilateral and contralateral hemispheres. After 10 mL/g of saline was added to individual samples, they were homogenized and centrifuged (13,000 rpm for 30 min). A 200 μL volume of reagent (QuantiChrom Hemoglobin Assay Kit; BioAssay Systems, CA, USA) was then added to 50 μL of supernatant. After 15 min, optical density was measured at 400 nm with a spectrophotometer (Skan It RE for Varioskan 133 Flash 2.4; Thermo Fisher Scientific, Waltham, MA, USA). Hemoglobin content index was calculated as ipsilateral hemoglobin content divided by contralateral hemoglobin content [26] .
Western Blot Analysis
Equal amounts of protein (100 μg) were separated by Trisglycine SDS-PAGE and transferred to polyvinylidene fluoride membranes. Based on our established protocols [27, 28] , membranes were blocked with 5 % skim milk and then incubated with the following primary antibodies overnight at 4°C:
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Results
Mortality Rates
Mortality was 0 (0/34) in the sham group, 11.7 % (4/34) in the vehicle group, 17.6 % (6/34) in the rtPA group, and 11.7 % (4/34) in the rtPA+TWS119 group. Mortality rate was not significantly different among the four groups (p>0.05).
TWS119 Decreased Neurologic Deficit Score in rtPA-Treated Rats
At 24 h after MCAO, neurologic deficit score of the vehicle group was lower than that of the rtPA group (n=34 rats/group, p<0.05, Fig. 1 ). However, the rtPA+TWS119 group (n=34 rats) had significantly lower neurologic deficit scores than did the rtPA group (p<0.05, Fig. 1 ). Thus, TWS119 improved the neurologic function in rtPA-treated MCAO rats. No neurologic deficit was present in the sham group (data not shown).
TWS119 Effectively Relieved Cerebral Edema in Rats Treated With rtPA
At 24 h after MCAO, the brain water content in rats that received rtPA was significantly higher than that of vehicletreated rats (n=6 rats/group, p<0.05, Fig. 2 ). Administration of TWS119 immediately after rtPA significantly decreased the brain water content compared to that in the group that received only rtPA (n=6 rats/group, p<0.05, Fig. 2 ). Brains from the sham group exhibited no cerebral edema.
TWS119 Reduced Cerebral Infarction in rtPA-Treated Rats
TTC staining was used to reveal the infarct area in the brain sections. Infarct volume in the rtPA group was significantly greater than that of the vehicle-treated MCAO group (n = 8 rats/group, p <0.05, Fig. 3 ). Administration of TWS119 reduced the infarct volume compared with that in the rtPA group (n = 8 rats/group, p< 0.05, Fig. 3 ). No infarct area was detected in the sham group (n = 8 rats/group, Fig. 3a ).
TWS119 Effectively Decreased Blood-Brain Barrier
Permeability in rtPA-Treated MCAO Rats EB dye leakage, used as an indicator of BBB permeability, was mainly concentrated in the regions of the ischemic hemisphere. We found that EBI in the rtPA group was significantly greater than that in the vehicle group (n=6 rats/group, p<0.05, Fig. 4 ) but was reduced by TWS119 treatment (n=6 rats/group, p<0.05, Fig. 4 ).
TWS119 Attenuated rtPA-Induced Hemorrhage in Ischemic Brain Tissue
Hemoglobin content index, which reflects the hemorrhage in ischemic brain tissues, was significantly higher in the rtPA group than in the vehicle group (n = 6 rats/group, p < 0.05, Fig. 5 ) but was significantly reduced by TWS119 treatment (n=6 rats/group, p<0.05, Fig. 5 ).
TWS119 Activated the Wnt/β-Catenin Signaling Pathway and Increased the Expression of Claudin-3 and ZO-1
Western blot analysis showed that the expression of tightjunction proteins claudin-3 and ZO-1 was significantly higher in the rtPA+TWS119 group than in the rtPA group (n=6 rats/group, p<0.01, Fig. 6 ). Additionally, β-catenin was upregulated and GSK-3β was downregulated in the rtPA+ TWS119 group compared to levels in the rtPA group (n=6 rats/group, p < 0.05, Fig. 6 ). These results suggest that TWS119 activates the Wnt/β-catenin signaling pathway and protects the BBB via regulation of claudin-3 and ZO-1.
Discussion
Reducing the risk of HT in patients treated with rtPA for ischemic stroke is a worldwide health challenge [3, 29] . In preclinical studies, a number of methods have decreased tPAinduced HT, including granulocyte colony-stimulating factor [2] , an optimized human apyrase [4] , and angiopoietin-1 [30] . However, no therapy has reduced the risk of HT clinically. In this study, we found that TWS119 activated the Wnt/β-catenin signaling pathway and protected the BBB from rtPA-induced HT after acute ischemic stroke in rats. According to our results, TWS119 significantly reduced neurologic deficit, infarction volume, and brain water content; decreased EB extravasation; and attenuated the rtPA-induced hemorrhage 24 h after MCAO. To our knowledge, this study is the first to report that TWS119 can provide protection after ischemic stroke with rtPA treatment. Previous studies have shown that BBB breakdown is the major cause of tPA-induced HT after acute ischemic stroke [31] [32] [33] . Damage to the composition or tight-junction proteins of the BBB usually leads to structural and functional disorders [34] . Therefore, focusing on protection of the BBB is quite important to reducing the risk of HT after tPA.
The conserved Wnt/β-catenin pathway regulates stem cell pluripotency and cell fate decisions during development [23, 35] . It is also involved in the brain's vascular development and BBB formation [9, 36] . Under pathologic conditions, a dysfunctional Wnt/β-catenin signaling pathway has been reported to contribute to BBB breakdown [9, 32] . However, no study has reported on the relationship between Wnt/β-catenin signaling pathway activation and tPA-induced HT in acute ischemic stroke. As such, we designed our experiments to close this gap. GSK-3β is involved in the degradation of β-catenin, which is a co-transcriptional factor and the key factor of the Wnt/β-catenin pathway [13, 14] . TWS119 is a specific inhibitor of GSK-3β. Therefore, by inhibiting GSK-3β, TWS119 will also inhibit the degradation of β-catenin and theoretically activate the Wnt/β-catenin signaling pathway. Indeed, we found that TWS119 decreased GSK-3β expression at 24 h after MCAO while increasing the amount of β-catenin protein [37] .
Because β-catenin is a key component of the Wnt/β-catenin pathway, enhancing its expression activates the downstream signaling pathway [38] . In our study, we found that TWS119 increased the expression of claudin-3 compared with that in the rtPA group. Claudin-3 is a gene downstream of the Wnt/β-catenin pathway. Its protein decreases paracellular permeability and increases transcellular electrical resistance, showing that it changes the tight-junction network and seals the paracellular pathway against the passage of small ions [39] . However, the expression of claudin-3 in the whole brain is rather low [40] , and its function in tPA-induced HT is still unresolved [41, 42] . ZO-1 is another important protein that controls endothelial adherens junctions, cell-cell tension, angiogenesis, and brain barrier formation [43, 44] . Both claudin-3 and ZO-1 are involved in induction and maintenance of the Fig. 5 TWS119 protects BBB and are the major transmembrane proteins that form the tight junctions of the BBB [45] . However, the changes in the expression of claudin-3 and ZO-1 during rtPA-induced HT and their relationship with Wnt/β-catenin signaling are currently unknown. Our results showed that expression levels of both claudin-3 and ZO-1 were increased in the TWS119 group compared with those in the rtPA group, suggesting that TWS119 protects against BBB disruption. Additional investigation is needed into the respective roles of these proteins and the mechanisms by which their expression increases. However, no standard in vitro or ex vivo model of HT is yet available with which to study deeper cellular and molecular mechanisms [46] .
Our results revealed that, in addition to protecting the integrity of the BBB, TWS119 treatment reduced infarct volume, brain edema and tPA-induced HT after MCAO. A recent study showed that the Wnt/β-catenin signaling pathway contributes to angiogenesis by regulating the expression of angiogenic factors such as vascular endothelial growth factor and matrix metalloproteinase (MMP)-9 [47] . Another study reported that the Wnt/ β-catenin signaling pathway is involved in the regulation of neuroinflammation [48] . Additional research is needed to determine whether Wnt/β-catenin signaling regulates neuroinflammation and MMP-9 activity, thereby underpinning TWS119-mediated protection after ischemic stroke. 
Conclusions
Our study showed that TWS119 activates the Wnt/β-catenin signaling pathway by inhibiting the expression of GSK-3β, thereby reducing rtPA-induced BBB disruption and subsequent HT after acute ischemic stroke. One possible mechanism by which this pathway might reduce HT is through increased expression of claudin-3 and ZO-1. Thus, the activation of Wnt/β-catenin signaling has the potential to protect the BBB and reduce HT in ischemic stroke after clinical rtPA administration. However, the specific mechanism needs additional study.
